Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 145Lymphoma, Follicular 41Lymphoma, Large B-Cell, Diffuse 37Lymphoma, B-Cell, Marginal Zone 24Recurrence 18Lymphoma, Mantle-Cell 17Lymphoma 16Neoplasms, Plasma Cell 15Lymphoma, Non-Hodgkin 15Leukemia, Lymphocytic, Chronic, B-Cell 11Neoplasms 9Lymphoma, B-Cell 8Smoldering Multiple Myeloma 7Burkitt Lymphoma 5Neoplasm, Residual 4Leukemia, Plasma Cell 4Waldenstrom Macroglobulinemia 3Myelodysplastic Syndromes 3Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell, Cutaneous 3Plasmacytoma 2Pancreatic Neoplasms 2Neuroblastoma 2Lymphoma, T-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Leukemia 2Hodgkin Disease 2Hematologic Diseases 2Dendritic Cell Sarcoma, Interdigitating 2

Interventions

Rituximab 1Lenalidomide 1CT-P10 1ALX148 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Composite Lymphoma × Lenalidomide × 1 year × Clear all
NCT05025800 2026-03-20

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Composite Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡